Refining diagnosis of Parkinson's disease with deep learning-based interpretation of dopamine transporter imaging

Hongyoon Choi, Seunggyun Ha, Hyung Jun Im, Sun Ha Paek, Dong Soo Lee

Research output: Contribution to journalArticlepeer-review

142 Scopus citations

Abstract

Dopaminergic degeneration is a pathologic hallmark of Parkinson's disease (PD), which can be assessed by dopamine transporter imaging such as FP-CIT SPECT. Until now, imaging has been routinely interpreted by human though it can show interobserver variability and result in inconsistent diagnosis. In this study, we developed a deep learning-based FP-CIT SPECT interpretation system to refine the imaging diagnosis of Parkinson's disease. This system trained by SPECT images of PD patients and normal controls shows high classification accuracy comparable with the experts’ evaluation referring quantification results. Its high accuracy was validated in an independent cohort composed of patients with PD and nonparkinsonian tremor. In addition, we showed that some patients clinically diagnosed as PD who have scans without evidence of dopaminergic deficit (SWEDD), an atypical subgroup of PD, could be reclassified by our automated system. Our results suggested that the deep learning-based model could accurately interpret FP-CIT SPECT and overcome variability of human evaluation. It could help imaging diagnosis of patients with uncertain Parkinsonism and provide objective patient group classification, particularly for SWEDD, in further clinical studies.

Original languageEnglish
Pages (from-to)586-594
Number of pages9
JournalNeuroImage: Clinical
Volume16
DOIs
StatePublished - 2017

Bibliographical note

Funding Information:
Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative database ( www.ppmi-info.org/data ). For up-to-date information on the study, visit www.ppmi-info.org . PPMI – a public-private partnership ( http://www.ppmi-info.org/ ) – is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including Abbvie, Avid Radiopharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Covance, Eli Lilly & Co, F Hoff man-La Roche, GE Healthcare, Genentech, GlaxoSmithKline, Lundbeck, Merck, MesoScale, Piramal, Pfizer, and UCB. This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea ( HI14C0466 ), and funded by the Ministry of Health & Welfare, Republic of Korea ( HI14C3344 ), and funded by the Ministry of Health & Welfare, Republic of Korea ( HI14C1277 ), and the Technology Innovation Program ( 10052749 ), and supported by the National Research Foundation of Korea (NRF) Grant funded by the Korean Government (MSIP) ( 2017M3C7A1048079 ). This study was also supported by the Korea Institute of Planning & Evaluation for Technology in Food, Agriculture, Forestry, and Fisheries , Republic of Korea ( 311011-05-3-SB020 ) by the Korea Healthcare Technology R&D Project funded by Ministry of Health & Welfare , Republic of Korea ( HI11C21100200 ) and by the Technology Innovation Program ( 10050154 , Business Model Development for Personalized Medicine Based on Integrated Genome and Clinical Information) funded by the Ministry of Trade, Industry & Energy (MI, Korea) and by the Bio & Medical Technology Development Program of the NRF funded by the Korean government, MSIP ( 2015M3C7A1028926 ) and by the National Research Foundation of Korea Grant Funded by the Ministry of Science and ICT ( NRF-2017M3C7A1047392 ).

Publisher Copyright:
© 2017 The Authors

Keywords

  • Deep learning
  • Deep neural network
  • FP-CIT
  • Parkinson's disease
  • SWEDD

Fingerprint

Dive into the research topics of 'Refining diagnosis of Parkinson's disease with deep learning-based interpretation of dopamine transporter imaging'. Together they form a unique fingerprint.

Cite this